Literature DB >> 1738086

HLA-B35 is associated with accelerated progression to AIDS.

S Itescu1, U Mathur-Wagh, M L Skovron, L J Brancato, M Marmor, A Zeleniuch-Jacquotte, R Winchester.   

Abstract

To investigate the influence of HLA specificities on the rate of progression and outcome of human immunodeficiency virus (HIV) infection, we performed (a) a case-control study in 1989-1990 of HIV-seropositive individuals stratified by both risk behavior and ethnic background, (b) a longitudinal cohort study of HIV-infected male homosexuals enrolled in 1981-1982, and (c) an analysis of individuals with a diffuse infiltrative CD8 lymphocytosis syndrome. In the case-control study, there was a significantly higher frequency of HLA-B35 among intravenous drug users, but not homosexuals, who developed illnesses meeting the case definition for AIDS compared with asymptomatic HIV-positive controls, regardless of ethnic status. In the longitudinal study, HLA-B35-positive homosexuals had a significantly increased rate of progression to AIDS and decreased survival over a 7-year period compared with those without this specificity. Finally, there was a significantly decreased frequency of HLA-B35 in individuals with the diffuse infiltrative lymphocytosis syndrome, a clinically and genetically distinctive disorder occurring in HIV infection in which a low rate of progression to opportunistic infections was found. The high rate of salivary and lacrimal gland lymphoma in this group suggests that there is dissociation between the presence of HLA-B35 and the development of particular AIDS-defining conditions. We conclude that HLA-B35 is a risk factor for more rapid progression to AIDS, particularly opportunistic infections and Kaposi's sarcoma, operating in groups with high rates of newly acquired HIV infections such as New York City male homosexuals in 1981-1982, and intravenous drug users in 1989-1990.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738086

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  26 in total

1.  How often does treatment of primary HIV lead to post-treatment control?

Authors:  Janine Maenza; Kenneth Tapia; Sarah Holte; Joanne D Stekler; Claire E Stevens; James I Mullins; Ann C Collier
Journal:  Antivir Ther       Date:  2015-04-23

2.  Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression.

Authors:  D T Evans; P Jing; T M Allen; D H O'Connor; H Horton; J E Venham; M Piekarczyk; J Dzuris; M Dykhuzen; J Mitchen; R A Rudersdorf; C D Pauza; A Sette; R E Bontrop; R DeMars; D I Watkins
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS.

Authors:  Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

4.  Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response.

Authors:  S Itescu; J Dalton; H Z Zhang; R Winchester
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503.

Authors:  Vilasack Thammavongsa; Malinda Schaefer; Tracey Filzen; Kathleen L Collins; Mary Carrington; Naveen Bangia; Malini Raghavan
Journal:  Immunogenetics       Date:  2009-12       Impact factor: 2.846

6.  Characterization of the primary structure of T cell receptor beta chains in cells infiltrating the salivary gland in the sicca syndrome of HIV-1 infection. Evidence of antigen-driven clonal selection suggested by restricted combinations of V beta J beta gene segment usage and shared somatically encoded amino acid residues.

Authors:  E Dwyer; S Itescu; R Winchester
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

8.  Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression.

Authors:  S Itescu; S Rose; E Dwyer; R Winchester
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

Review 9.  Immunogenetics of HIV disease.

Authors:  Maureen P Martin; Mary Carrington
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis.

Authors:  Kenneth C Williams; Tricia H Burdo
Journal:  APMIS       Date:  2009-05       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.